Reuters logo
BRIEF-Myriad Genetics’s supplementary PMA for BRACAnalysis CDx accepted by FDA for review
2017年10月18日 / 中午11点30分 / 1 个月前

BRIEF-Myriad Genetics’s supplementary PMA for BRACAnalysis CDx accepted by FDA for review

Oct 18 (Reuters) - Myriad Genetics Inc

* Myriad’s BRACAnalysis CDx supplementary pma accepted by fda for review as a companion diagnostic for Lynparza (olaparib) in metastatic breast cancer

* Myriad Genetics Inc - ‍Myriad expects FDA‘S priority review process to conclude in fiscal third-quarter 2018​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below